Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisOld and new treatment targets in axial spondyloarthritisInflammation, bone loss and fracture risk in spondyloarthritisEffects of anti-tumor necrosis factor α agents on boneMeta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trialsInfliximab: 12 years of experienceBone mass in axial spondyloarthritis: A literature review.Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention studySerum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.The epidemiology of osteoporosis and fractures in ankylosing spondylitis.The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study.Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesSerum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.Insight on Bone Morphogenetic Protein 7 in Ankylosing Spondylitis and its association with disease activity and radiographic damage.Recent advances in neutralizing the IL-6 pathway in arthritis.Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management?HLA-B27 alters the response to tumor necrosis factor α and promotes osteoclastogenesis in bone marrow monocytes from HLA-B27-transgenic rats.Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trialsProgress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis.Osteoporosis in inflammatory joint diseases.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Osteoporosis: a paradox in ankylosing spondylitis.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Biomarkers of cartilage and surrounding joint tissue.The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis.Osteoporosis Management in Ankylosing Spondylitis.Decreased Serotonin Levels and Serotonin-Mediated Osteoblastic Inhibitory Signaling in Patients With Ankylosing Spondylitis.Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort.The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis.Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort.Predicting pathway cross-talks in ankylosing spondylitis through investigating the interactions among pathways.Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
P2860
Q21245284-2A44654B-DD0A-4430-B3A8-69E22B4329DBQ26774173-F54D7AB7-B27E-43A7-B1D7-F55271737520Q26777906-FD84FBB2-2E3B-4DBB-B4CF-9AFEA7AC9A4AQ26778258-2490D46E-6D16-4D45-B5A1-AAF53843DE1DQ26851274-1A204A12-63CD-47A0-B7EB-F3D2EEE2A2DBQ27025358-6B13BFE4-ACEF-4EC9-8E4F-A7EAD0073350Q35070446-BE5600BE-3FE7-439F-AB96-1B9F7F2991A2Q35188767-6983B7E4-15C9-4B53-BC6C-8BDBC27727BAQ35809286-6B041490-3C78-4E3D-806C-02A0EE12F4E3Q35820405-EEEB8A88-C914-484C-A7C5-089B72B814E2Q35896663-4A00E54F-C132-420A-BDD0-B3B67FE9FD32Q36111291-F17E3D27-6350-4548-9F9E-B379C825455EQ36245903-AC720841-0C83-477D-8C16-A37D48FB1AC6Q36781280-9686149C-D46C-4393-8056-729517A114ABQ36993320-2243A6D5-3832-4260-91EF-8D0BAC0CD3C5Q37238870-A411CDD6-0AC4-4CE8-AEBC-32E88FD71FE5Q37358099-F0C425B9-9F2C-40AC-9807-D4EF03C86C1DQ37358225-59DD409F-E622-4D27-8785-3E79BC813236Q37378182-46739E4B-8CC7-4E88-90AE-208D4E1412D5Q37465459-99F4D74A-644B-408B-B929-AA22B9D5922FQ37480069-C2944C32-777A-42FA-B5DD-E7CC10DC7DDDQ37765505-DD773640-717F-45F7-8FB1-373C04079C73Q37801555-C7B67A70-C9F0-4620-8880-2808B1EB9C7AQ37885790-CF132B91-6515-4497-BF6F-FA6E5B1DD727Q38041419-91F9B32D-7D43-44BD-83A1-1CD11D5BA1B1Q38239828-B118A466-BFA2-432E-8BB2-538FDC266603Q38265675-7265EFFB-1BD7-42C5-B437-61264789097AQ38670399-C0AB4150-4C10-45EE-8708-0A67FDB785C2Q38831392-781E82D7-6916-47E7-875F-A7E864BB745BQ41371671-71AB19DF-35EA-41A9-8522-58B1D20BA2D1Q44934503-F03ECF39-C5BA-4ADD-B0C9-A875176069DFQ45299337-44BEAF16-DDB0-4C84-A8BC-42FCB5AC88A3Q45941107-915C8C24-A5EB-4FD7-9D69-5971280219D0Q51626383-DB3E3C24-1C42-4C40-AA5B-56B00F14ABB1Q52874129-C7E7FE1D-45AB-4AE8-967C-D169551728EAQ53116508-3CC0E449-8C4D-4438-8E5D-E726BE6D6467
P2860
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@en
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@nl
type
label
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@en
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@nl
prefLabel
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@en
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@nl
P2093
P2860
P356
P1476
Effects of infliximab on marke ...... s with ankylosing spondylitis.
@en
P2093
P2860
P304
P356
10.1136/ARD.2007.084426
P407
P577
2008-05-21T00:00:00Z